Federated Hermes’s ANI Pharmaceuticals ANIP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.2M | Buy |
26,577
+3,592
| +16% | +$288K | ﹤0.01% | 1004 |
|
|
2026
Q1 | $1.77M | Sell |
22,985
-8
| -0% | -$624 | ﹤0.01% | 996 |
|
|
2025
Q4 | $1.82M | Buy |
22,993
+21,979
| +2,168% | +$1.9M | ﹤0.01% | 977 |
|
|
2025
Q3 | $92.9K | Buy |
+1,014
| New | +$82.7K | ﹤0.01% | 1588 |
|
|
2024
Q4 | – | Sell |
-118
| Closed | -$7.04K | – | 2075 |
|
|
2024
Q3 | $7.04K | Sell |
118
-8
| -6% | -$488 | ﹤0.01% | 1830 |
|
|
2024
Q2 | $8.02K | Buy |
126
+6
| +5% | +$390 | ﹤0.01% | 1799 |
|
|
2024
Q1 | $8.3K | Buy |
120
+7
| +6% | +$423 | ﹤0.01% | 1795 |
|
|
2023
Q4 | $6.23K | Sell |
113
-98
| -46% | -$5.4K | ﹤0.01% | 1832 |
|
|
2023
Q3 | $12.3K | Buy |
211
+14
| +7% | +$808 | ﹤0.01% | 1810 |
|
|
2023
Q2 | $10.6K | Buy |
+197
| New | +$8.73K | ﹤0.01% | 1843 |
|
|
2022
Q4 | – | Sell |
-8
| Closed | -$1K | – | 2160 |
|
|
2022
Q3 | $1K | Sell |
8
-13
| -62% | -$445 | ﹤0.01% | 2004 |
|
|
2022
Q2 | $1K | Sell |
21
-263,753
| -100% | -$7.61M | ﹤0.01% | 2020 |
|
|
2022
Q1 | $7.42M | Sell |
263,774
-3
| -0% | -$112 | 0.02% | 684 |
|
|
2021
Q4 | $12.2M | Sell |
263,777
-13,078
| -5% | -$562K | 0.02% | 596 |
|
|
2021
Q3 | $9.09M | Buy |
276,855
+14,270
| +5% | +$444K | 0.02% | 672 |
|
|
2021
Q2 | $9.2M | Buy |
262,585
+43
| +0% | +$1.46K | 0.02% | 684 |
|
|
2021
Q1 | $9.49M | Sell |
262,542
-12,208
| -4% | -$382K | 0.02% | 677 |
|
|
2020
Q4 | $7.98M | Sell |
274,750
-17,671
| -6% | -$506K | 0.02% | 696 |
|
|
2020
Q3 | $8.25M | Sell |
292,421
-8,447
| -3% | -$252K | 0.02% | 618 |
|
|
2020
Q2 | $9.73M | Buy |
300,868
+230,832
| +330% | +$8.28M | 0.02% | 547 |
|
|
2020
Q1 | $2.85M | Buy |
+70,036
| New | +$3.72M | 0.01% | 788 |
|
|
2019
Q3 | – | Sell |
-92
| Closed | -$8K | – | 2201 |
|
|
2019
Q2 | $8K | Buy |
+92
| New | +$6.54K | ﹤0.01% | 1922 |
|
|
2018
Q3 | – | Sell |
-162
| Closed | -$11K | – | 2249 |
|
|
2018
Q2 | $11K | Buy |
+162
| New | +$10.1K | ﹤0.01% | 1890 |
|
|
2018
Q1 | – | Sell |
-189
| Closed | -$12K | – | 2154 |
|
|
2017
Q4 | $12K | Buy |
+189
| New | +$11.8K | ﹤0.01% | 1850 |
|
|
2017
Q1 | – | Sell |
-4,081
| Closed | -$247K | – | 2118 |
|
|
2016
Q4 | $247K | Sell |
4,081
-5,822
| -59% | -$356K | ﹤0.01% | 1467 |
|
|
2016
Q3 | $657K | Buy |
9,903
+1,839
| +23% | +$115K | ﹤0.01% | 1210 |
|
|
2016
Q2 | $450K | Buy |
8,064
+5,756
| +249% | +$280K | ﹤0.01% | 1302 |
|
|
2016
Q1 | $78K | Buy |
+2,308
| New | +$78.3K | ﹤0.01% | 1592 |
|
|
2015
Q2 | – | Sell |
-74
| Closed | -$5K | – | 1950 |
|
|
2015
Q1 | $5K | Sell |
74
-41
| -36% | -$2.49K | ﹤0.01% | 1861 |
|
|
2014
Q4 | $6K | Buy |
+115
| New | +$5.07K | ﹤0.01% | 1802 |
|
Other funds holding ANIP
SCM
TCM
GACM
Federated Hermes's ANIP Position: Q2 2026 in Review
Federated Hermes increased its ANI Pharmaceuticals (ANIP) stake by 16% in Q2 2026, buying an estimated $288K and bringing the position to 26,577 shares worth $2.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1004.
Federated Hermes first reported a position in ANIP in Q4 2014 and has held it in 30 quarters since. The position peaked at $12.2M in Q4 2021. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.
- Federated Hermes held 26,577 shares of ANI Pharmaceuticals worth $2.2M as of Q2 2026.
- Federated Hermes bought 3,592 ANI Pharmaceuticals shares in Q2 2026, an estimated $288K.
- ANI Pharmaceuticals made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1004 holding.
- Federated Hermes first reported a position in ANI Pharmaceuticals in Q4 2014 and has held it in 30 quarters since.
- Federated Hermes's ANI Pharmaceuticals position peaked at $12.2M in Q4 2021.
- 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.
Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.